Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Kory et al., FLCCC Alliance (Preprint) (meta analysis)
Kory et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of.., FLCCC Alliance (Preprint) (meta analysis)
Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been widely used, showing efficacy of ivermectin in prophylaxis and treatment of COVID-19.There is potentially inaccurate data collection and/or reporting in some included trials.Currently there are 95 ivermectin studies and meta analysis shows:
risk of death, 69.0% lower, RR 0.31, p < 0.001, treatment 35 of 1,551 (2.3%), control 191 of 1,957 (9.8%), NNT 13, odds ratio converted to relative risk.
Abstract: Review of the Emerging Evidence Demonstrating the Efficacy of
Ivermectin in the Prophylaxis and Treatment of COVID-19
Pierre Kory, MD1*, G. Umberto Meduri, MD2†, Jose Iglesias, DO3, Joseph Varon, MD4, Keith
Berkowitz, MD5, Howard Kornfeld, MD6, Eivind Vinjevoll, MD7, Scott Mitchell, MBChB8, Fred
Wagshul, MD9, Paul E. Marik, MD10
1
2
3
4
5
6
7
8
9
10
Front-Line Covid-19 Critical Care Alliance
Memphis VA Medical Center, Univ. of Tennessee Health Science Center, Memphis, TN
Hackensack School of Medicine, Seton Hall, NJ.
Chief of Critical Care at United Memorial Medical Center in Houston, TX
Center for Balanced Health, New York
Recovery Without Walls
Volda Hospital, Volda, Norway
Princess Elizabeth Hospital, Guernsey, UK
Lung Center of America, Dayton, Ohio
Eastern Virginia Medical School
* Correspondence:
Corresponding Author: Pierre Kory, MD, MPA
pkory@flccc.net
1 These authors have contributed equally to this work
† Dr. Meduri’s contribution is the result of work supported with the resources and use of facilities
at the Memphis VA Medical Center. The contents of this commentary do not represent the views
of the U.S. Department of Veterans Affairs or the United States Government
Keywords
Ivermectin, COVID-19, infectious disease, pulmonary infection, respiratory failure
Abstract
In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by
Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and
clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered that
ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties
against COVID-19. They then identified repeated, consistent, large magnitude improvements in clinical outcomes in multiple, large, randomized and observational controlled trials in both prophylaxis
and treatment of COVID-19. Further, data showing impacts on population wide health outcomes have
www.flccc.net
Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
[FLCCC Alliance; updated Jan 16, 2021]
2 / 30
resulted from multiple, large “natural experiments” that occurred when various city mayors and
regional health ministries within South American countries initiated “ivermectin distribution” campaigns to their citizen populations in the hopes the drug would prove effective. The tight, reproducible,
temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin may prove to be a global
solution to the pandemic. This was further evidenced by the recent incorporation of ivermectin as a
prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Belize,
Macedonia, and the state of Uttar Pradesh in Northern India, populated by 210 million people. To our
knowledge, the current review is the earliest to compile sufficient clinical data to demonstrate the
strong signal of therapeutic efficacy as it is based on numerous clinical trials in multiple disease
phases. One limitation is that half the controlled trials have been published in peer-reviewed publications, with the remainder taken from manuscripts uploaded to medicine pre-print servers. Although
it is now standard practice for trials data from pre-print servers to immediately influence therapeutic
practices during the pandemic,..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.